ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

WSJ BLOG/Health: A.M. Vitals: Health-Care Overhaul Case Ripples Outward

(This story has been posted on The Wall Street Journal Online's Health Blog at By Mark Long Here's what's making health news this morning: Health Case Ripples Outward (WSJ): After three days of arguments over the constitutionality of the health-care overhaul, it's impossible to predict how the Supreme Court will rule, but skepticism from some justices heightens the possibility it could be overturned in June. Also: Three Days of Hearings Yield Five Take-Aways. Obesity-Linked Cancers Increase (WSJ): Overall cancer diagnoses in the U.S. have dropped, but several cancers linked to obesity and a sedentary lifestyle have risen each year from 1999 through 2008. Cancer: 'Book of Knowledge' Published (BBC): A large "encyclopedia" detailing how hundreds of different cancer cell lines interact with drugs that could speed development of new treatments was published in Nature. In Cancer Science, Many "Discoveries" Don't Hold Up (Reuters): Forty-seven of 53 "landmark" cancer studies from reputable labs couldn't be replicated, the former head of cancer research for Amgen said in a commentary piece in Nature, dimming the prospects for new drug development. FDA Asks Chelsea Therapeutics for More Data on Northera (Dow Jones Newswires): The FDA declined to approve Northera, a low-blood-pressure drug from Chelsea Therapeutics, saying additional data showing efficacy was required. Image source: iStockphoto -For continuously updated news from The Wall Street Journal, see at

Stock News for Amgen Inc. (AMGN)
10/25/201605:30:00Amgen To Invest In Israel-Based eHealth Ventures
10/24/201616:00:00Amgen Announces Webcast Of 2016 Third Quarter Financial Results
10/20/201616:19:00Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab...
10/14/201616:10:03Current Report Filing (8-k)
10/14/201616:05:00Amgen Announces 2016 Fourth Quarter Dividend
10/14/201616:00:00Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
10/10/201609:09:00New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment...
10/05/201616:10:00New Amgen Data In Melanoma And Metastatic Colorectal Cancer To...
10/04/201616:00:00Amgen To Participate In Citi Biotech R&D Conference Call
10/03/201616:09:00Study Results Published In Journal of Clinical Oncology Show...
09/29/201609:51:00Amgen, Arrowhead Pharma Agree to Cardiovascular Collaboration
09/29/201607:30:00Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular...
09/28/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
09/27/201608:32:00Amgen's Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27/201604:00:00Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib...
09/26/201617:00:00Amgen Opens Nomination Process For LabCentral Residency
09/26/201616:00:00Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License...
09/23/201620:12:00FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23/201619:10:00FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23/201618:56:00FDA Approves Amgen's Biosimilar Version of Humira

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations